
Intellia Therapeutics Inc (NASDAQ:NTLA) shares are soaring on Thursday after the company completed enrollment in its crucial Phase 3 HAELO trial and laid out its key development milestones.
What Happened: Intellia announced that it concluded patient enrollment in the global Phase 3 HAELO study of lonvoguran ziclumeran (lonvo-z) within nine months of dosing the first subject.